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Problem Definition

Methods/Results, Continued

Survey Results

Multiple studies (e.g. EMPA-REG, CANVAS) demonstrate that
SGLT2 Inhibitors (Inh) improve cardiac outcomes in patients with
Type II Diabetes (DM2) with comorbid Cardiovascular Disease
(CVD) including Heart Failure and Coronary Artery Disease.

What We Found: 100 patients met inclusion criteria:
§ 50 patients were seen by endocrinology and met criteria to be
on SGLT2. 10/50 (20%) were on SGLT2 inhibitors.
§ 95 patients were seen by cardiology and met criteria to be on
SGLT2. 11/95 (11.6%) were on SGLT2 inhibitors.
§ 8 patients were seen by internal medicine and met criteria to
be on SGLT2, 0/8 (0%) were on SGLT2 inhibitors.
§ 13 patients were seen by only family medicine and met criteria
to be on SGLT2, 1/13 (7.7%) was on SGLT2 inhibitors.
* In total 100 patients qualified for SGLT2 inhibitor
therapy. 13/100 (13%) were on SGLT2 inhibitors.

SGLT2 Inhibitors are considered standard of care for patients with
DM2 and CVD.
Based on literature published in European Journal of Preventative
Cardiology and JACC HF, our prediction is that physicians at
Thomas Jefferson University Hospital Ambulatory Practices (TJUH)
under-utilize SGLT2 Inh for patients with co-morbid CVD and
DM2.

Measurement Strategy
Less Comfortable

More Comfortable

Process: # patient charts reviewed by Endo CRNP, # patients
initiated on SGLT2 Inh while inpatient
Outcome: % physicians comfortable prescribing SGLT2 Inh, #
patients who are being prescribed SGLT2 Inh
Balancing: medication affordability, education fatigue,
availability for education

Aims For Improvement
Lessons Learned & Next Steps/Future Interventions

Within the Jefferson Healthcare System, we sought to determine:

What Was Implemented?
- Creation of a cardiac metabolic task force led by Cardiology and
Endocrinology with a goal to work collaboratively to increase
the rate of the SGLT2 Inhibitor use in these target populations.
- Informational Card was posted in outpatient offices.

1. The percentage of patients with an indication for an SGLT2
Inhibitor who were actually being prescribed this.
2. How often providers within the Jefferson system were
prescribing these medications, and what the barriers to
prescribing are.
With this information, we hoped to increase the percentage of
(qualifying) patients who are on these medications as part of
standard of care by 20% within one year of intervention.

Take a picture to explore
more results of our
survey.

Next Steps/Work in Progress:

Methods/Results
Part 1: We surveyed physicians from Cardiology,
Internal Medicine, Family Medicine, and
Endocrinology to assess:
- physician comfort level and frequency of prescribing
SGLT2 Inh
- subjective importance of SGLT2 Inh in patients with
DM2 and CVD
- which medical specialties should prescribe SGLT2 Inh

Lessons Learned: Provider comfort levels, improvement takes time
and requires “buy-in”, may need a change in culture, an
individual’s comfort level/awareness strongly drives outcomes.

Survey
Questions

Part 2:
1. We collected a random sample of patients (n=200) known to
any of the above departmental TJUH outpatient clinics.
2. We performed a retrospective chart review to determine the
percentage of patients with DM2 and CVD (heart failure,
coronary artery disease) who were appropriately prescribed an
SGLT2 Inhibitor.

- June 2020: dedicated Endocrine CRNP funded by ADA to work
in Cardiology reviewing patient charts for SLT2 Inh indication.
- Two SGLT2 Inhibitors will be on formulary
- Endocrinologists working with Cardiology/IM/Nephrologylectures, Q&A
- Collaborations with ADA
* One year from the time changes are implemented, the survey and
patient data will be repeated and re-analyzed to determine if we
met our aim for improvement *

